Prodromal Parkinson's disease: hype or hope for disease-modification trials?

Abstract

The ultimate goal in Parkinson's disease (PD) research remains the identification of treatments that are capable of slowing or even halting the progression of the disease. The failure of numerous past disease-modification trials in PD has been attributed to a variety of factors related not only to choosing wrong interventions, but also to using inadequate trial designs and target populations. In patients with clinically established PD, neuronal pathology may already have advanced too far to be modified by any intervention. Based on such reasoning, individuals in yet prediagnostic or prodromal disease stages, may provide a window of opportunity to test disease-modifying strategies. There is now sufficient evidence from prospective studies to define diagnostic criteria for prodromal PD and several approaches have been studied in observational cohorts. These include the use of PD-risk algorithms derived from multiple established risk factors for disease as well as follow-up of cohorts with single defined prodromal markers like hyposmia, rapid eye movement sleep behavior disorders, or PD gene carriers. In this review, we discuss recruitment strategies for disease-modification trials in various prodromal PD cohorts, as well as potential trial designs, required trial durations, and estimated sample sizes. We offer a concluding outlook on how the goal of implementing disease-modification trials in prodromal cohorts might be achieved in the future.

Background

Parkinson’s disease (PD) continues to be clinically defined by a set of cardinal motor features anchored on the presence of bradykinesia and at least one additional motor symptom out of rest tremor or rigidity [1, 2]. Neuropathological evidence suggests that these motor symptoms only emerge after 40%–60% of neurons in the substantia nigra have been lost and striatal dopamine levels are reduced by 60%–70% [3, 4]. Even prior to the onset of nigral neurodegeneration, extranigral Lewy-body pathology is believed to affect the peripheral autonomic nervous system, the caudal brainstem, as well as the olfactory bulb [5] and may correlate to a variety of early nonmotor symptoms that have been shown to antedate the first appearance of classical motor signs [2, 6–8]. Along these lines, population-based or other cohort studies have established a significantly increased risk of developing PD in otherwise healthy subjects with hyposmia, constipation, depression, excessive daytime somnolence, and idiopathic rapid eye movement (REM) sleep behavior disorder (RBD) [9–15]. For people with idiopathic RBD, conversion into a clinically overt neurodegenerative disorder, most commonly PD or dementia with Lewy-bodies (DLB), has been estimated to occur at a rate of around 6% per year [16], strongly suggesting that a large proportion of those subjects are actually in a stage of prodromal Lewy-body disease. This and other evidence leave little doubt that the onset of PD pathology in the nervous system occurs much earlier than is captured by the current definition of clinical disease onset (Table 1) [17, 18].

Table 1.

Conceptual stages of Parkinson’s disease (PD)

Phases of PD [17, 18]	Clinical status	Pathology	Comments
Phase 1—preclinical PD	No clinical signs or symptoms	PD-specific pathology assumed to be present	Supported by biomarkers (genetic, molecular, and/or imaging)
Phase 2—prodromal PD	Early nonmotor symptoms ± early subtle motor symptoms	Extranigral PD pathology (Braak stages 1 and 2) ± nigral PD pathology (< 40%–60% cell loss; Braak Stage 3)	Research criteria defined based on clinical nonmotor markers (± motor markers) and nonclinical biomarkers. There may be various levels of certainty [18]; probable prodromal PD defined at ≥ 80% probability (sufficiently certain for disease-modification trials) [24] and possible prodromal PD (lower, but still substantial likelihood, e.g., 30%–80%)
Phase 3—clinically established PD	Classical motor manifestations are present	Nigral PD pathology (> 40%–60% cell loss; Braak stages 3 to 6)	Current clinical diagnostic criteria based on motor syndrome are met [1]; ± a variety on nonmotor symptoms may be present due to extranigral extension of PD pathology

The ultimate goal of identifying subjects in the prodromal stages of PD is to offer therapies that are able to modify the course of the disease in that they delay or even prevent the development of clinically established PD and related disability (Panel 1). Indeed, the failure of trials of disease-modifying interventions in PD to date may in part be due to the fact that pathology in established PD is too advanced for the respective treatments to be effective [19, 20]. If this is the case, then targeting prodromal PD would offer much greater chances of success for future trials. Also, disease-modification trials targeting subjects in the prodromal phase of the disease would not have to account for the confounding effects of established symptomatic PD therapies, which has been a significant issue in past trials in early PD.

In this review, we discuss potential target populations and recruitment strategies for disease-modification trials in prodromal PD as well as potential trial designs, required trial durations, and estimated sample sizes. We offer a concluding outlook on how the goal of disease-modification trials in prodromal cohorts might be achieved in the future.

Panel 1: Conceptual framework of disease-modification in Parkinson’s disease (PD)

- Disease-modification

Any therapy that alters the clinical course (‘natural history’) of a disease can be regarded as ‘disease-modifying’. Such a broad definition would also include symptomatic therapies for PD as they reduce the severity and functional impact of motor and non-motor symptoms and thus positively influence the progression of disability. However, in regulatory science (and in the context of this review), the term disease-modification is used in a narrower sense, i.e., for a therapy that is capable of positively influencing the course of the disease by biological mechanisms that revert disease-specific pathophysiological changes [20, 21]. Such mechanisms may include not only slowing or halting the otherwise progressive loss of monoaminergic neurons (i.e., neuroprotection), but also improving downstream signaling processes and compensatory responses. - Neuroprotection The term ‘neuroprotection’ was introduced to capture beneficial (protective) effects of an intervention on neuronal survival and function. While such neuroprotective effects can be expected to translate into clinically detectable disease-modification, the presumed underlying biological effect on neuronal survival cannot be proven during lifetime without validated biomarkers that are closely linked to the disease-specific neuronal pathology. In the context of PD, such biomarkers are currently lacking. Previous trials have used molecular imaging markers of pre-synaptic nigro-striatal terminal function as a surrogate for measuring nigral cell loss, but this technique is not able to distinguish between functional effects of an intervention and effects on neuronal survival. - Disease-prevention The term ‘disease-prevention’ is tempting to use in the context of trials in prodromal cohorts, as prevention of clinically established PD can be seen as the ultimate goal of disease-modifying interventions in such subjects. However, there are conceptual problems even here, given that prodromal disease stages are, by definition, already a disease state. Nonetheless, in a broader sense, the term can be used to describe effects of an intervention that forestall the development of clinically overt PD. In this review, we include such effects under the umbrella term of (early) disease-modification. - Regulatory definitions of disease-modification in PD The European Medical Agency requires a two-step procedure to demonstrate disease-modification in PD – first, a delay in clinical measures of disease progression should be shown and, second, an effect on the underlying pathophysiological process which correlates to a meaningful, and persistent changes in clinical function [22]. The Food and Drug Administration (FDA) has not published guidance related to PD. However, in their latest guidance related to drug development in early Alzheimer’s disease, the term ‘disease-modifying’ has been replaced by ‘persistent effect on disease course’ that should be accompanied by a ‘direct effect on the underlying disease pathophysiology’ [23].

Identifying prodromal PD as a target population for disease-modification trials

Based on a solid body of evidence from prospective studies of risk factors for the development of PD [9–15], two principal approaches to identifying subjects with high likelihood of harboring prodromal PD have been used. They include multifactorial screening algorithms for PD risk on the one hand and approaches targeting single specific risk or prodromal markers like hyposmia or RBD with subsequent enrichment steps on the other hand. Carrier status for monogenic PD genes is a third and much narrower starting point.

To date, there are some published risk scores that have been developed in relation to their predictive performance for incident PD [24–27]. The two best studied and most comprehensive screening multi-item algorithms are the online-based PREDICT-PD risk score [27, 28] and the Movement Disorders Society (MDS) research criteria for prodromal PD [24, 29]. The PREDICT-PD algorithm incorporates remotely-assessable early non-motor features and risk factors combined into a risk score that in the original study was associated with incident PD during follow-up over 3 years with a hazard ratio of 4.4 [27]. Two validation attempts showed weaker, but significant associations of the score with incident PD, with odds ratios of 1.3–2.1 [30, 31]. An enhanced PREDICT-PD risk score has recently been developed that integrates three additional markers and showed better accuracy in predicting PD compared with the original score [32].

The MDS criteria were specifically designed to calculate probabilities of prodromal PD in a given subject, where an 80% threshold is the cut-off for a diagnosis of ‘probable prodromal PD’ (see Fig. 1 for schematic structure of the MDS criteria) [24]. They are novel in that they do not only make use of single risk factors or specific combination of a selection thereof. In fact, they aim at including all established PD risk and prodromal markers, thereby generating a comprehensive picture of an individual’s risk profile that is integrated in a probability score (similar to risk scores in cardiovascular medicine). In 2019, a first update of the criteria was presented, which incorporated new evidence for risk and prodromal markers already included and supplemented them with four new markers [29]. While prospective evaluations of the criteria and their update are awaited, evidence from retrospective applications of the criteria to existing longitudinal population-based cohorts seems promising [33–36]. They consistently reported high specificity and negative predictive values (NPV) in identifying incident cases of PD, while sensitivity and positive predictive values (PPV) varied substantially, dependent on the type of study population (enriched risk vs population-based), depth of marker assessment, and length of follow-up time. Interestingly, a high predictive accuracy of the MDS criteria has also been detected in a cohort study in 121 patients with idiopathic RBD (PPV 81%; for conversion into PD or dementia with Lewy bodies over 4 years) [37] and a cohort of leucine-rich repeat kinase 2 (LRRK2) mutation carriers (PPV 47%–67%) [38].

Fig. 1.

Schematic structure of MDS research criteria for prodromal PD. The approach by the MDS task force entails 1. assessment of pretest probability for prodromal PD based on age, 2. the sequential addition of LRs of various risk and prodromal markers, and 3. the calculation of post-test probabilities using the above information (see Berg  et al. 2015 [24] for further details).

Modified from Mahlknecht et al. 2018 [34], with kind permission from Wiley. * Markers added with the 2019 update of the MDS research criteria for prodromal PD [29]. EDS, excessive daytime somnolence; LR, likelihood ratio; OH, orhtostatic hypotension; PD, Parkinson’s disease; SN, substantia nigra

The second type of approach uses single established PD risk factors for an initial screen with subsequent enrichment for high risk of ‘conversion’ into clinically PD. Such strategies make use of sequential screening steps of increasing specificity, starting with easily assessable and ideally sensitive markers – candidate markers may include positive family history, hyposmia, subtle motor impairment, probable RBD, or combinations thereof [39–42]. Subsequent enrichment steps would use additional clinical biomarkers such as neuroimaging, polysomnography or genetic assessment. The prospective PRIPS (Prospective evaluation of Risk factors for Idiopathic Parkinson’s Syndrome) study has found that by using prescreening for age (> 50 years), primary screening for positive family history and/or hyposmia, and secondary screening for substantia nigra hyperechogenicity, one out of 16 positively screened participants developed PD over 3 years (PPV of 6.1%) compared to one out of 135 in the original cohort [41]. This is clearly insufficient to meet the requirements of a feasible disease-modification trial with incident PD as an endpoint. Similarly, the prospective Parkinson associated risk syndrome (PARS) study used a first screening step of olfactory function assessment with University of Pennsylvania Smell Identification Test (UPSIT) mailings in subjects aged > 50 years and found that of 152 hyposmic individuals followed-up over 4 years, 19 (12.5%) developed PD [43]. However, when adding dopamine transporter (DAT) single-photon emission computed tomography (SPECT) as an enrichment screen, 14 of 21 with a DAT-SPECT deficit (and hyposmia) developed PD, resulting in a PPV of 67%.

Patients with idiopathic RBD seem to represent a particularly useful target population as the majority of patients with idiopathic RBD (> 80%) will convert into a neurodegenerative disorder – most commonly PD, PD dementia (PDD), or DLB [11]. Annualized conversion rates to PD (52%) or DLB (44%) have averaged ~ 6% per year in the most recent multicenter RBD longitudinal series [16]. However, median latency to conversion can be as long as 12 to 14 years [11, 12]. This seriously limits the feasibility of trials with a phenoconversion endpoint in idiopathic RBD patients. Several studies have found that the addition of other clinical markers such as hyposmia [13, 16, 44], abnormal color vision [16, 44], or subtle motor dysfunction [13, 16, 44] can result in high conversion rates over shorter periods of time. This would, however, reduce the size of available cohorts. Potential solutions for this problem would be multicenter efforts to collect large-enough patient samples and/or to enlarge existing patient cohorts by population-based RBD screening (such as in the recently started Luxembourg's National Sleep Survey; https://www.rbd.lu, last accessed 12/2021). Another caveat for idiopathic RBD patients in this context is that conversion not only occurs to PD but with similar frequency also to DLB and more rarely to multiple system atrophy (MSA), such that trials in idiopathic RBD patients would inform on disease-modification in Lewy Body disorders and synucleinopthies in general.

Figure 2 illustrates potential screening strategies in the general community for target populations for disease-modification trials assuming three different approaches, in which substantial conversion rates to clinically overt PD (> 60% over 5 or less years) have been described. The numbers of individuals from the general elderly population needed to be screened to obtain such samples are significant. Such numbers would perhaps be feasible to screen with online approaches similar to the one used in the PREDICT PD algorithm [27], with published strategies for RBD screening in the population [45–47], or risk scores using data originating from primary care presentations and general practitioners [26].

Fig. 2.

Potential screening strategies for target populations for disease-modification trials in the general community assuming three different target populations (PPV > 60%). First column: individuals with hyposmia and DAT-Deficit; real numbers from the PARS study that used olfactory testing as first remote screening step and DAT-Scan as a second screen are presented [43]. These include losses to follow up. Second column: patients with idiopathic RBD and further marker(s) that indicate increased risk for early conversion as hyposmia, abnormal color vision, or subtle motor dysfunction (approximately one third of idiopathic RBD patients) [13, 44]; the identification of idiopathic RBD patients from the general community is modeled using a questionnaire as a first remote screening step (assuming a prevalence of probable RBD of 5%) [46, 48] and polysomnography as a second screening step (assuming that approximately one sixth of probable RBD cases are confirmed as having idiopathic RBD) [45, 46]. Third column: Individuals with probable prodromal PD according to the MDS research criteria as modeled from data of the prospective population-based Bruneck Study [34]; remote screening includes a questionnaire-based assessment and brief odor-identification test. The model envisages that all participants reaching a post-test probability for prodromal PD of > 10% (one quarter of participants) are invited for the in person screening including a motor examination and transcranial sonography. Estimated numbers necessary for remote screening are derived from the prevalence of probable prodromal PD (i.e. 2.2%). Please note that only multipliers in the first column account for losses to follow-up, whereas the ones in the second and third columns do not

Finally, asymptomatic carriers of mutations in monogenic PD genes, e.g. LRRK2, or in risk genes like glucocerebrosidase (GBA), identified as first-degree relatives of PD patients, also represent potential prodromal target populations for disease-modification trials [19, 49, 50]. Such cohorts are attractive, since they have a defined underlying molecular disease mechanism that can be targeted with specific (‘personalized’) interventions. However, since penetrance is incomplete, the application of additional biomarkers that can indicate conversion into manifest PD in shorter time-frames would be necessary for this group as well. The MDS criteria could again be a suitable instrument for this purpose. When applied to a multicenter cohort of 120 LRRK2 mutation carriers (first-degree relatives of LRRK2 PD patients), of whom only 10 converted to PD over 5 years, the cut-off for prodromal PD status yielded a PPV of 47%–67% [38]. Despite these obstacles, an obvious hope is that eventual disease-modifying mechanisms identified in such genetic groups are generalizable and that developed treatments might subsequently be successfully applied to sporadic PD patients.

Role of biomarkers in identifying prodromal PD

Even if comprehensive instruments such as the MDS prodromal criteria enabled detection of individuals with prodromal PD at high accuracy, it would be desirable to have a highly specific confirming biomarker as a last step before inclusion of participants into disease-modification trials in order to reduce false-positives to a minimum. Ideally, such a biomarker would also indicate disease progression and therefore represent an additional outcome measure as a surrogate marker of disease-modification. Previous studies have mainly used molecular imaging of the nigrostriatal dopaminergic system, in particular DAT imaging. In the PARS study, hyposmic individuals with a baseline DAT deficit (below the 65% age-expected lowest putamen binding ratio) experienced a futher 4-year 20% decline in DAT binding (equaling to an annual 5% reduction similar to early PD) compared with 4%–5% in those with only intermediate or no DAT-deficit [43]. Future imaging candidates may include promising, but yet to be validated magnetic resonance imaging (MRI)-based biomarkers that are specific for PD (e.g., nigrosome-1, free-water, or neuromelanin imaging of the substantia nigra) [51–56] and show change over time. Real-time quaking-induced conversion (RT-QuIC) identifying pathologically folded α-synuclein at high sensitivity constitutes another emerging and potentially suitable biomarker for this purpose. In one study, RT-QuIC-identified pathogenic α-synuclein in the cerebrospinal fluid (CSF) had a sensitivity of 95% and a specificity of 98% in discriminating PD, DLB, and idiopathic RBD from controls, atypical parkinsonian disorders and Alzheimer’s disease [57]. The same method was also found to be predictive of development of PD or DLB in idiopathic RBD patients [58]. Alternative approaches for biospecimen collection for RT-QuIC analysis are skin biopsies with a similarly high diagnostic yield [59–61] and, although less sensitive, olfactory mucosa by nasal swabs [62].

Trial design issues for disease-modification trials in prodromal PD

Traditionally, disease-modifying trials have been performed in early disease stages of established PD and have, so far, mostly shown negative or inconclusive results despite numerous attempts applying different treatments, trial designs, and outcome variables [2, 19, 20]. The most prominent examples in the form of high-quality and rigorous randomized controlled trials (RCTs) assessed disease-modifying properties of selegiline and tocopherol (DATATOP) [63], levodopa (ELLDOPA and LEAP) [64, 65], pramipexole (PROUD) [66], rasagiline (ADAGIO) [67], creatine (NET-PD) [68], and exenatide (EXENATIDE-PD) [69]. Trial designs comprised of simple two-arm double-blind approaches with time to need for levodopa [63], or change in motor status as assessed with the UPDRS after 2-week [64] or 12-week [69] washout period as endpoints, or delayed-start approaches with change in motor status according to the UPDRS as endpoint [65–67]. Some of these trials additionally assessed biological imaging outcomes as surrogates for disease-modification, such as change in presynaptic nigrostriatal dopaminergic dysfunction with radiotracer imaging [64, 66]. Multiple factors may have contributed to the many failures in this field, including the type of intervention, target population, clinical trial design, choice of the primary outcome measures, and trial duration.

When planning disease-modification trials in prodromal PD populations, some additional conceptual issues and caveats have to be taken into account. For the most intuitive endpoint of conversion into PD, a simple long-term RCT trial with time-to-event analysis would be suitable. However, definition of phenoconversion has some challenges and there are reasons for choosing continuous outcomes such as motor or non-motor progression (see following sections), for which both classical parallel-group or delayed-start designs could be used [20, 70]. However, using progression of motor or non-motor features also poses some issues since—unlike in early PD—progression rates of disease-related clinical dysfunction in motor or non-motor domains are poorly defined and there is hardly any sensitive and validated non-clinical progression biomarker. These obstacles result in many uncertainties regarding suitable trial endpoints and durations.

Endpoints

Table 2 delineates examples for potential outcomes of disease-modification trials in prodromal PD. Conversion to clinically established PD seems to represent the most obvious primary endpoint. It has already been used in many observational studies of prodromal PD cohorts [13, 33, 34, 37, 38, 44], some of which also calculated sample sizes required for disease-modifying trials (see next section) [13, 16, 34, 44]. The assessment of the exact disease onset in such high-risk populations, however, is rather subjective and observer-dependent and comes with an inherent risk of poor standardization and heterogeneity in multi-center trials [71].

Table 2.

Examples of potential endpoints for disease-modification trials in prodromal PD

Type of marker	Outcome (endpoint)	Availability of data from studies in prodromal cohorts	Availability of data from studies in early PD patients	Advantages	Disadvantages
Clinical marker	Phenoconversion to clinically defined PD	Assessed in many unselected and preselected population-based cohorts [27, 33, 34, 38, 43], assessed in iRBD [13, 37, 44, 73]	NA	Represents the essence of prophylactic therapies	May require long trial duration of 5 or more years, difficulties in determining the exact time point of phenoconversion
	Motor progression (e.g., motor parts of the MDS-UPDRS/UPDRS)	Assessed in population-based [74] and iRBD cohorts [75, 76]	Assessed in early PD patients [77–79]; MDS-UPDRS Part II scores increased 1.0 point per year, and Part III scores increased 2.4 points per year, steepest increment observed in year 1	Shorter intervals due to continuous outcome	Motor progression might be slow in the early “premotor” phase (but accelerates shortly before diagnosis and in very early PD)
	Non-motor progression	Assessed in population-based [74] and iRBD cohorts [75, 76]	Assessed in early PD patients [78, 80]	Non-motor progression may be faster in “premotor” stages than motor progression	Heterogeneous outcome
	Progression of the prodromal PD score	Assessed in TREND [33], PMPP [81], and in a LRRK2 cohort [38]; results suggest the progression may only be seen in true prodromal PD cases that may indeed go on to develop PD	NA	Universal outcome that seems to be very different in true prodromal cases versus healthy controls	Large interindividual variability [33]
Imaging marker	Decline in striatial dopaminergic binding	Assessed in the PARS cohort (5% decline per year) [43] and in iRBD patients (6% decline per year) [82]	Assessed in early PD patients in the PPMI cohort [79] and in disease-modification trials [64, 66]	Objective, quantifiable, correlates with disease severity	Represents surrogate marker, expensive, requires multiple resources
	Progression of MRI markers [53]	NA	Free-water imaging [83] Neuromelanin imaging [84, 85]	Objective, quantifiable, correlates with disease severity	Represents surrogate marker, expensive, requires specialized MRI
Biochemical marker	Change in alpha-synuclein in CSF	Assessed in individuals with prodromal PD in the PPMI cohort [86]	Assessed in the PPMI cohort [86, 87]	Lower in PD patients and individuals with prodromal PD	No change over time observed in early PD patients; no correlation with disease progression or ongoing neurodegeneration in MDS-UPDRS and DAT-Scan results; contradicting results
	RT-QuIC-assessed alpha-synuclein	Assessed only as disease state biomarker [58, 62]; but not yet as progression biomarker	Assessed only as disease state biomarker [57, 59–61]; but not yet as progression biomarker	Highly sensitive	Not yet assessed in term of progression marker. Specialized lab equipment

CSF, cerebrospinal fluid; DAT, dopamine transporter; iRBD, idiopathic REM-sleep behaviour disorder; LRRK2, leucine-rich repeat kinase 2; MDS, Movement Disorders Society; MRI, magnetic resonance imaging; NA, not assessed; PMPP, Progression Markers in the Premotor Phase study; PPMI, Parkinson’s progression marker initiative; TREND, Tuebinger evaluation of Risk factors for Early detection of NeuroDegeneration study; UPDRS, Unified Parkinson’s Disease Rating Scale; RT-QuIC, Real-time quaking-induced conversion

Clinical rating scales providing continuous indices of progression of motor and non-motor dysfunction have been standard outcome measures of past disease-modification trials in early PD, but almost none have revealed significant treatment effects over periods of 1–2 years. While this may have been a problem of the interventions, the problem of using these outcomes will be even greater in prodromal PD where there is very limited information on their rates of progression. Compared to disease-modification trials in early PD, there is an even greater need for sensitive and meaningful progression biomarkers in trials in the prodromal stage of the disease. DAT imaging is an example, for which there are published progression rates from the PARS study (i.e., ~ 5% decline per year in putaminal binding). Other measures may include advanced MRI-based analyses like neuromelanin or free-water imaging of the substantia nigra. The most attractive imaging biomarker would require the availability of alpha-synuclein position emission tomography (PET) tracers [72]—similar to beta-amyloid imaging in Alzheimer’s disease. Alpha-synuclein seeding assays in CSF or tissues like skin or olfactory mucosa have shown very promising diagnostic performance in PD and also prodromal cohorts with idiopathic RBD [57, 58, 62], but so far they have not been tested or validated regarding their sensitivity to measure disease progression. Efforts are underway to make alpha-synuclein aggregation seeding assays quantifiable for use as a marker for biological drug effects, which would be of great significance for early-stage clinical trials (for example for alpha-synuclein immunization trials).

In general, large prospective natural-history studies in the general population and prodromal PD cohorts will more clearly delineate progression of clinical and biomarker indices over time. To this end, the prospective Parkinson Progression Marker’s Initiative (PPMI) has been expanded to include prodromal PD cohorts including subjects with hyposmia or RBD who meet a threshold for DAT deficit as well as genetic mutations in LRRK2, GBA, or SNCA (https://www.ppmi-info.org/study-design; last accessed 12/2021). It is hoped that prodromal PPMI and other prospective studies will provide robust natural history data of progression of clinical and biomarker indices in prodromal PD.

Sample sizes and trial duration

The basic key considerations that influence decisions on sample size and duration of a PD trial are summarized in Panel 2. With regard to disease-modification trials in neurodegenerative disorders such as PD, there are particular challenges that are further amplified when targeting prodromal disease stages. PD is generally slowly progressive, requiring longer trial durations in the range of at least 2–3 years in order to detect significant changes in clinically relevant outcomes. This would likely have to be even longer to detect effects on progression in prodromal PD. Prodromal PD populations with high likelihood of phenoconversion like subjects with idiopathic RBD or asymptomatic carriers of LRRK2 mutations also have a low prevalence compared to clinically established early PD.

Nonetheless, there are viable strategies that could potentially be used for recruitment. Figure 2 shows three examples for target population recruitments from the general community that have a > 60% likelihood of reaching the endpoint of conversion into clinically identifiable PD or DLB. For an outcome of phenoconversion, the number of events can be increased either by choosing higher-risk patients, by increasing the follow-up time, or by increasing the sample size. Most observational studies in prodromal PD have been performed in an attempt to identify rates of conversion into manifest PD (± DLB) with a given set of risk/prodromal markers in various populations. Some of these studies have also reported estimations for sample sizes for disease-modification trials that would use a phenoconversion endpoint: in our own population-based study, sample size estimates at 80% power in an intention-to-treat approach ranged from 108 to 540 subjects with probable prodromal PD depending on trial duration (3–5 years) and effect size of the agent (30%–50%) [34]. For example, in an intention-to-treat approach, a total of 540 and of 294 individuals with probable prodromal PD would be required to have an 80% chance to detect a 30% decrease in the primary outcome measure of conversion to PD for 3 years and 5 years, respectively. The numbers for a more efficient intervention at 50% effect size would be substantially lower (190 and 108 individuals, respectively). However, our estimations rely on a low number of converters only, may therefore not be precise, and must be reassessed in future prospective population-based studies. There are other studies that assessed sample sizes in idiopathic RBD cohorts. Idiopathic RBD is thought to be the most specific marker with the highest PPV with a conversion rate of 80% into a Lewy-body disorder. However, the median latency to conversion into clinically defined PD or DLB can be as long as 12–14 years [11, 12], seriously limiting the feasibility of disease-modification trials in idiopathic RBD cohorts. In fact, in the largest idiopathic RBD cohort published so far, Postuma et al. found conversion rates of 6% per year with 52% converting into PD and 44% into DLB [16]. Various markers were assessed for their potential to identify those patients at high risk of early conversion and, thus, those suitable for inclusion into disease-modification trials. Based on the time-to-event analysis, the authors estimated that 366 unselected idiopathic RBD patients per arm would be needed for a 2-year trial at 80% power to find a 50% reduction in disease phenoconversion [16]. The most powerful single selection procedure was abnormal motor testing, which reduced sample size to 166–197 patients; however, only one third of idiopathic RBD patients had abnormal testing, thus excluding two thirds of patients from such a trial. Abnormal olfaction was present in two thirds of patients and reduced sample size to 247–262, and a probable prodromal PD status according to MDS criteria was present in three quarters of patients and yielded sample sizes of 282–301 per group.

In another recent monocenter analysis on progression of prodromal markers in patients with idiopathic RBD who also met the definition of probable prodromal PD status as per MDS criteria, motor progression on the UPDRS was the marker associated with lowest sample size requirements, but was not more powerful than time to phenoconversion with both endpoints requiring approximately 240 patients per arm (2-year trial at 80% power and 50% efficacy) [76]. The most efficient design was a time-to-event analysis using milestones of motor and cognitive decline (e.g., 126 per group when using rise in UPDRS III ≥ 4 points or a MoCA decline ≥ 3 points) as primary endpoints.

Panel 2: Trial duration and sample size—basic key considerations

Sample sizes for clinical trials should be large enough and trial durations long enough to avoid the type II or β error (i.e., falsely accepting the null hypothesis H0; meaning that a significant difference could be detected using larger samples or longer trial durations). Sample-size estimations depend on 5 factors: 1. The type I or α error (i.e., the likelihood of false positive results by falsely rejecting the null hypothesis H0), which is usually set at 5%. 2. The power equaling to 1-β, which is usually set at 80% or 90%. 3. The estimated effect size of the intervention (e.g., 30% reduction of worsening or occurrence of an outcome measure). 4. The assumed dropout rate: the intention-to-treat estimations do also consider dropouts in studies and are therefore more conservative as compared with per protocol analyses. This is particularly important for disease-modification trials in PD, which require long durations. 5. The variability in the occurrence of the outcome—for disease-modification trials with a binary endpoint (e.g., time to phenoconversion) this is equivalent to the estimated percentage of trial participants that potentially meet the endpoint. This obstacle can be overcome by evidence from robust natural history data in large prodromal cohorts.

Conclusions and outlook

Although PD stands out among the neurodegenerative diseases by the availability of highly efficacious symptomatic therapies, none of these treatments can prevent the inevitable long-term progression of disease into serious motor and non-motor disability [2, 88, 89]. After more than 20 years of frustration with failed ‘neuroprotection’ or ‘disease-modification’ trials, there is now new hope that a breakthrough may eventually become possible. This optimism is mainly driven by major advances that have occurred in two research areas over the last decade and have opened new opportunities to finally achieve successful disease-modification in PD. One is related to the ability to identify subjects in the prodromal or ‘pre-diagnostic’ stage of PD, where underlying molecular pathologies may still be reversible or at least more responsive to targeted interventions. As outlined in this article, there are still important challenges to overcome when planning trials in such populations, but an important beginning has been made. The other highly significant progress made in recent years concerns a growing understanding of the molecular pathways involved in PD pathogenesis—primarily driven by unravelling the genetic architecture of PD. This has revealed a multitude of novel targets for disease-modification, and a growing number of interventions addressing such targets have been and are being tested in clinical trials in early PD [19, 20]. But again, there have also been disappointments with some of these new targeted interventions like alpha-synuclein antibodies or substrate reduction therapies for glucocerebrosidase enzyme in GBA-positive patients with PD [90–92], suggesting a need for alternative approaches. Among these, targeting prodromal instead of early clinically diagnosed PD seems to offer enhanced potential for success. However, a number of obstacles have still to be removed as the field gets ready to embark on this route.

One of this is the painful lack of progression biomarkers that are sensitive to detect intervention effects within shorter time frames than are currently needed for clinical outcomes and that are closely linked to clinical progression and outcome. The availability of alpha-synuclein PET tracers could potentially respond to that need [72], similar to beta-amyloid imaging in Alzheimer’s disease. The discussion around this has gained momentum after the recent FDA approval for the anti-amyloid Alzheimer drug adecanumab that was primarily based on intervention effects on the imaging biomarker. However, the resulting controversy about this regulatory decision has also highlighted the issues around the use of biomarker outcomes that are not underpinned by concurrent effects on clinical measures [93]. Even if a one-year trial in prodromal PD could demonstrate efficacy of an intervention on a validated progression biomarker, there will still be a need for a longer controlled extension to demonstrate translation into clinically relevant effects.

A second major challenge to address relates to concerns that the ‘one drug fits all’ approach that has been used in all disease-modification trials in PD so far, ignores patient heterogeneity in terms of underlying molecular pathologies and may thus obscure the disease subtype-specific efficacy of an intervention [94]. Future trials in prodromal PD will have to deal with this, for example, by selecting target populations with specific molecular pathologies for corresponding target-specific interventions—like the use of kinase-inhibitors in LRRK2 mutation carriers [50]. In order to roll out such ‘personalized’ strategies beyond prodromal monogenic PD subtypes, there is still a largely unmet need for a biomarker-supported platform to identify pathogenetic disease subtypes. In the context of sporadic PD, potential subtypes of PD have been defined in the PPMI cohort of early PD patients differentiating between a ‘diffuse malignant’ type, a ‘mild motor predominant’, and an ‘intermediate’ type [95]. The malignant PD phenotype is characterized by higher motor deficits and non-motor symptom burden in terms of cognitive impairment, RBD, and dysautonomia, and is associated with faster progression and higher risk for major disease milestones and death [95, 96]. Similarly, a ‘body-first’ PD subtype with early dysautonomia and RBD and a ‘brain-first’ subtype of PD have recently been described according to the presumed site of initiation of PD pathology [97–99]. While being of high interest to the field of prodromal PD [94], these concepts have so far only been assessed in a few studies in manifest PD and idiopathic RBD and their relevance for the planning of future disease-modification trials is still unclear.

At the other end of the spectrum, successful disease-modification in prodromal PD might eventually require drug combinations addressing multiple targets, not unlike what is common practice in primary prevention of cardiovascular disease. The latter example also highlights the potential role of life-style modifications in reducing disease risk, an area that has been explored to some extent in neurodegenerative diseases like PD or Alzheimer’s disease, where physical and mental activity, dietary, drinking and smoking habits, as well as control of vascular co-morbidities have been shown to modify disease risk [100–102]. While there are significant challenges regarding controlled prospective studies of the effects of such factors on the evolution of disease in prodromal subjects, they would nonetheless be essential for individual patients [103] and for evidence-based PD risk-management at the public health level.

Integrating screening for PD risk and prodromal PD into public health programs is the ultimate goal once effective therapies to delay or prevent progression to manifest PD will have become available. However, many of the required screening criteria in the public health context [104, 105] are not yet fully met for PD. Importantly, there are several ethical issues that need consideration also in relation to research efforts of identifying prodromal PD subjects. ‘Medicalization’ is a social phenomenon when individuals, who receive a screening invitation, may become worried on the possibility of having the disease [106, 107]. Overdiagnosis is another well-known problem in the oncology literature for controversial cancer screening tests which aim at early cancer detection such as mammography and prostate-specific antigen screening [107], and refers to the detection of subclinical disease (sometimes called pseudodisease) which would not have become manifest clinically in someone’s remaining lifetime [108, 109]. Depending on a given health care system, a positive screening result, i.e. diagnosis of prodromal PD, can have significant impact on the access to health care or life insurances [110]. Moreover, diagnostic accuracy of a screening procedure is of major concern, and predictive values for manifest PD of current diagnostic criteria for prodromal PD are still suboptimal. False-positive results of a screening procedure give rise to unnecessary further diagnostic tests and create worries of having a disease that may never manifest. Examples are not only subjects with false positive prodromal risk score results, but also patients with idiopathic RBD that are now commonly medically defined as harboring PD, PDD/DLB, or MSA, although a minority may remain free of any symptoms of such disease for decades or their entire life-span. Risk disclosure strategies should therefore take factors such as prodromal status (e.g., RBD-positive versus RBD-negative) into account [111]. Inviting subjects to join trials or other research in prodromal PD requires careful individualized counseling and an option for psychosocial support.

Despite all the challenges and unmet needs discussed in this review, the PD field has probably never been as close to a fulfillment of James Parkinson’s prophecy of 1817 as it is in 2022: “there appears to be sufficient reason for hoping that some remedial process may ere long be discovered, by which, at least, the progress of the disease may be stopped”.

Abbreviations

CSF

Cerebrospinal fluid

DAT

Dopamine transporter

DLB

Dementia with Lewy-bodies

FDA

Food and Drug Administration

GBA

Glucocerebrosidase gene

LRRK2

Leucine-rich repeat kinase 2 gene

MRI

Magnetic resonance imaging

MSA

Multiple system atrophy

NPV

Negative predictive values

PD

Parkinson’s disease

PDD

Parkinson’s disease dementia

PARS study

Parkinson associated risk syndrome study

PET

Position emission tomography

PPV

Positive predictive values

PPMI

Parkinson Progression Marker’s Initiative

RT-QuIC

Real-time quaking-induced conversion

RBD

Rapid eye movement sleep behavior disorder

UPDRS

Unified Parkinson’s disease rating scale

UPSIT

University of Pennsylvania Smell Identification Test

Authors' contributions

PM, KM, KS, and MW wrote the first draft of the manuscript based on an idea conceived by KS and WP. WP wrote the conclusion section. PM and KM created illustrations. All authors contributed to revising the manuscript. All authors have read and approved the final manuscript.

Funding

There was no specific funding for this article. P.M.: reports lecture fees from Boston Scientific outside the submitted work and a grant from the Tiroler Wissenschaftsförderung (Grant UNI-0404/2245). K.M.: has been supported by a grant from the Tiroler Wissenschaftsförderung (Grant UNI-0404/2245). M.W.: Nothing to report. W.P.: reports personal fees from Alterity, AbbVie, Affiris, AstraZeneca, BIAL, Biogen, Britannia, Lilly, Lundbeck, Neuroderm, Neurocrine, Denali Pharmaceuticals, Novartis, Orion Pharma, Roche, Takeda, Teva, UCB, and Zambon (consultancy and lecture fees in relation to clinical drug development programs for PD); royalties from Thieme, Wiley Blackwell, Oxford University Press, and Cambridge University Press; and grant support from MJFF; EU FP7, and Horizon 2020 outside the submitted work. K.S.: reports personal fees from Teva, UCB, Lundbeck, AOP Orphan Pharmaceuticals AG, Roche, Grünenthal, Stada, Licher Pharma, Biogen, and Abbvie; honoraria from the International Parkinson and Movement Disorders Society; and research grants from FWF Austrian Science Fund, Michael J. Fox Foundation, and AOP Orphan Pharmaceuticals AG, outside the submitted work.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

All authors have given their consent for publication.

Competing interests

The authors declare no competing interests.